Suven Pharmaceuticals Future Growth
Future criteria checks 6/6
Suven Pharmaceuticals is forecast to grow earnings and revenue by 45.1% and 42% per annum respectively. EPS is expected to grow by 37% per annum. Return on equity is forecast to be 21% in 3 years.
Key information
45.1%
Earnings growth rate
37.0%
EPS growth rate
Pharmaceuticals earnings growth | 17.2% |
Revenue growth rate | 42.0% |
Future return on equity | 21.0% |
Analyst coverage | Low |
Last updated | 13 Feb 2025 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 41,312 | 10,811 | N/A | N/A | 1 |
3/31/2026 | 34,554 | 8,636 | N/A | N/A | 1 |
3/31/2025 | 25,898 | 6,058 | N/A | N/A | 1 |
12/31/2024 | 10,485 | 2,792 | N/A | N/A | N/A |
9/30/2024 | 9,612 | 2,431 | 1,885 | 2,838 | N/A |
6/30/2024 | 9,345 | 2,405 | N/A | N/A | N/A |
3/31/2024 | 10,514 | 3,003 | 3,067 | 3,585 | N/A |
12/31/2023 | 11,678 | 3,709 | N/A | N/A | N/A |
9/30/2023 | 13,017 | 4,318 | 3,130 | 4,318 | N/A |
6/30/2023 | 13,491 | 4,243 | N/A | N/A | N/A |
3/31/2023 | 13,403 | 4,113 | 1,713 | 4,572 | N/A |
12/31/2022 | 13,348 | 3,790 | N/A | N/A | N/A |
9/30/2022 | 13,726 | 4,313 | 2,522 | 4,787 | N/A |
6/30/2022 | 13,952 | 4,563 | N/A | N/A | N/A |
3/31/2022 | 13,202 | 4,538 | 2,548 | 3,300 | N/A |
12/31/2021 | 12,155 | 4,453 | N/A | N/A | N/A |
9/30/2021 | 10,989 | 3,988 | 2,561 | 3,465 | N/A |
6/30/2021 | 10,353 | 3,759 | N/A | N/A | N/A |
3/31/2021 | 10,097 | 3,623 | 2,717 | 3,825 | N/A |
12/31/2020 | 9,353 | 3,534 | N/A | N/A | N/A |
9/30/2020 | 8,391 | 2,977 | 2,518 | 3,843 | N/A |
6/30/2020 | 8,746 | 3,166 | N/A | N/A | N/A |
3/31/2020 | 8,338 | 3,170 | 3,039 | 4,069 | N/A |
3/31/2019 | 9,068 | 2,623 | -153 | 1,210 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUVENPHAR's forecast earnings growth (45.1% per year) is above the savings rate (6.7%).
Earnings vs Market: SUVENPHAR's earnings (45.1% per year) are forecast to grow faster than the Indian market (17.7% per year).
High Growth Earnings: SUVENPHAR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SUVENPHAR's revenue (42% per year) is forecast to grow faster than the Indian market (10.6% per year).
High Growth Revenue: SUVENPHAR's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SUVENPHAR's Return on Equity is forecast to be high in 3 years time (21%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/16 11:57 |
End of Day Share Price | 2025/02/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suven Pharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
Nikhil Shetty | BP Wealth Management Private Limited |
Vinod T.P. | Geojit Financial Services Ltd. |